Variant Creutzfeldt Jakob Disease

Slide 1 · Variant Creutzfeldt-Jakob Disease

A transmissible prion disorder: clinicopathologic distinctions

Prion biology • BSE linkage • spongiform pathology • diagnostic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain how pathogenic prion protein propagates by templated conformational change.

Relate bovine spongiform encephalopathy exposure to human vCJD.

Distinguish vCJD from classic CJD clinically and morphologically.

Interpret spongiform change, florid plaques, and diagnostic evidence.

Slide 3 · VCJD within the human prion diseases

Prion disorders share abnormal prion-protein accumulation and spongiform degeneration.

CJD, Gerstmann–Sträussler–Scheinker syndrome, fatal familial insomnia, and kuru affect humans.

Variant CJD is a transmitted prion disease, not simply early-onset sporadic CJD.

The clinical phenotype and plaque distribution distinguish the variant syndrome.

Slide 4 · How vCJD emerged as a distinct syndrome

Unusual CJD-like cases were recognized in the United Kingdom beginning in 1995.

Patients were notably younger than those with typical sporadic CJD.

Behavioral abnormalities were conspicuous early in the illness.

Neurologic progression was slower than in classical CJD.

Slide 5 · The label “variant” has clinicopathologic meaning

Conventional CJD

Variant CJD

Usually begins with rapidly progressive cognitive decline.

Most frequently occurs later in adult life.

Prion-associated spongiform degeneration is characteristic.

Frequently begins with psychiatric or behavioral change.

Usually affects comparatively young individuals.

Numerous cortical florid plaques help characterize pathology.

Slide 6 · The zoonotic route to vCJD

BSE-infected cattle

Contaminated bovine food products

Human prion exposure

Variant CJD

Epidemiologic and experimental evidence links the human syndrome to bovine spongiform encephalopathy.

Slide 7 · Why the BSE association is causal, not just temporal

VCJD emerged in a population affected by bovine spongiform encephalopathy.

The implicated exposure was consumption of contaminated food derived from cattle.

Multiple convergent lines of evidence support transmission from the bovine disease.

This is an example of a species barrier being crossed by a pathogenic protein.

Slide 8 · Two transmission pathways described for vCJD

Primary acquisition

Secondary transmission

Exposure to material contaminated by the BSE agent.

Food-associated exposure initiated the recognized outbreak.

Clinical illness may emerge long after exposure.

Blood from a person with preclinical vCJD can transmit infection.

The infectious period is not limited to overt neurologic disease.

This creates specific blood-safety challenges.

Slide 9 · Why preclinical blood transmission matters

An infected person may lack recognizable neurologic symptoms for years.

Blood collected before symptom onset can still carry a transmission risk.

Clinical screening alone cannot identify every preclinical carrier.

Blood-donor policies and surveillance address this exposure route.

Slide 10 · Prion transmission differs from ordinary infection

The propagating entity is a misfolded host protein rather than a conventional microbial genome.

Introduced pathogenic PrP can induce conversion of normal PrP.

An exposure event may precede apparent illness by many years.

Mechanistic models must separate exposure, propagation, and overt neurodegeneration.

Slide 11 · Long clinical latency can conceal prior exposure

Exposure

Preclinical propagation

Neuropathologic accumulation

Symptoms and progression

Incubation is measured over years; The onset of neuropsychiatric illness does not identify the moment of infection.

Slide 12 · Public health response to a transmissible prion disease

Recognition of the BSE–vCJD association triggered population-level control measures.

Reducing contaminated cattle-product exposure addresses primary human transmission.

Blood-safety policies address possible person-to-person spread.

The United Kingdom epidemic declined markedly after the public-health response.

Slide 13 · A short historical sequence

UK cases noticed: 1995

BSE link recognized

Population-level controls

UK incidence peak: 2000

The incidence subsequently fell sharply, supporting the importance of upstream exposure prevention.

Slide 14 · The UK epidemic is not the same as sporadic CJD incidence

VCJD was an exposure-associated event in a specific historical setting.

Classic sporadic CJD generally results from rare spontaneous misfolding events.

Both syndromes involve PrP misfolding, but their epidemiologic mechanisms differ.

A decline in vCJD does not imply disappearance of other prion disorders.

Slide 15 · Typical age differs markedly

Classic CJD: Median age at death

Variant CJD: Median age at death

68 years

28 years

Median values from the CDC clinical comparison; Ranges overlap and age alone is not diagnostic.

Slide 16 · VCJD usually has a longer symptomatic course

Classic CJD: Median illness

Variant CJD: Median illness

4–5 months

13–14 months

These are typical group-level courses, not individual prognostic guarantees.

Slide 17 · Early symptoms in vCJD often appear psychiatric

Early behavioral or psychiatric changes are part of the characteristic syndrome.

An initially psychiatric presentation can delay recognition of a neurological disorder.

Progression beyond isolated psychiatric symptoms is a crucial diagnostic clue.

Exposure context modifies suspicion but cannot establish disease alone.

Slide 18 · Sensory symptoms may precede overt dementia

Persistent painful dysesthesia may occur early in the clinical course.

Sensory symptoms have more discriminating value when paired with progressive psychiatric illness.

Neither pain nor dysesthesia is specific for vCJD in isolation.

A temporal history should document the order in which manifestations appeared.

Slide 19 · A characteristic clinical progression

Psychiatric or sensory onset

Progressive neurologic abnormalities

Ataxia / movement abnormalities

Cognitive decline and dependency

The sequence is a typical pattern rather than an obligatory order for every patient.

Slide 20 · Neurologic signs emerge as disease advances

Ataxia may reflect involvement of cerebellar and related neural circuits.

Myoclonus or other involuntary movements may subsequently appear.

Progressive cognition impairment becomes prominent later.

The evolution from neuropsychiatric to multi-domain neurologic disease is informative.

Slide 21 · Classic CJD versus vCJD: Presenting emphasis

Classic CJD

Variant CJD

Rapidly progressive dementia is a dominant clinical feature.

Startle myoclonus is often prominent.

Ataxia occurs in some affected individuals.

Early behavioral or psychiatric symptoms receive greater emphasis.

Younger age shifts the initial clinical differential.

Subsequent neurologic decline generally takes longer.

Slide 22 · Clinical exercise: The early phase

Illustrative teaching vignette (not a real patient)

An otherwise healthy young adult develops persistent behavioral change followed by unusual painful sensory complaints. There is no established explanation at initial assessment.

Clinical interpretation

Which features warrant a longitudinal neurologic history?

Why is vCJD a differential diagnosis rather than an immediate conclusion?

Slide 23 · Clinical exercise: Progression changes the differential

Illustrative teaching vignette (not a real patient)

Months later, the same illustrative patient develops gait incoordination, involuntary movements, and cognitive deterioration.

Clinical interpretation

Which evolution increases suspicion of a progressive prion disorder?

What exposure history and investigations become especially relevant?

Slide 24 · Normal and disease-associated prion proteins

Normal PrPᶜ

Abnormal PrPˢᶜ

The host’s normal prion-protein conformer.

Relatively α-helical architecture.

Does not itself define prion disease.

Conformationally altered, β-sheet–enriched isoform.

Relatively resistant to proteinase K digestion.

Promotes further PrP conversion and aggregates.

Slide 25 · A conformational change initiates propagation

PrPᶜ: Normal conformer

Conversion to PrPˢᶜ

Template-driven conversion

Progressive PrPˢᶜ accumulation

The protein’s pathogenic behavior follows altered conformation, not synthesis of a new pathogen-encoded protein.

Slide 26 · Propagation depends on templated protein conversion

Once present, PrPˢᶜ facilitates the conversion of additional PrPᶜ molecules.

Newly converted molecules can act as further templates.

This self-amplifying process accounts for transmissibility.

The mechanism links molecular misfolding to progressive tissue deposition.

Slide 27 · Initiation and propagation are separate stages

Initiation

Propagation

Rare spontaneous change can start sporadic CJD.

Inherited PRNP alterations can favor the transition.

Exogenous PrPˢᶜ can seed transmitted disease.

PrPˢᶜ converts host PrPᶜ molecules.

Aggregate burden grows in the nervous system.

Progressive neuronal injury produces the clinical syndrome.

Slide 28 · Three routes to human prion disease

Route

How the misfolded seed arises

Representative context

Sporadic

Very rare spontaneous PrP change

Most conventional CJD

Inherited

PRNP mutation increases transition

Familial prion disorders

Acquired

Pathogenic PrP from external material

VCJD; Iatrogenic CJD; Kuru

Slide 29 · Why proteinase K resistance is useful

Normal PrPᶜ

Protease exposure

PrPᶜ is digested

Compared with the normal form, abnormal PrPˢᶜ is relatively resistant and can be detected after partial proteolysis.

Slide 30 · Protease resistance is a biochemical marker

Conformational change modifies susceptibility to proteolytic degradation.

Proteinase K digestion can enrich detection of disease-associated PrP.

PrP immunodetection after controlled digestion supports pathologic identification.

Protease resistance is a diagnostic property, not an explanation for every toxic effect.

Slide 31 · How prion accumulation injures neurons remains uncertain

Accumulated PrPˢᶜ is strongly linked to the characteristic degenerative lesions.

The precise causal route from aggregate deposition to cytoplasmic vacuoles is unresolved.

The mechanisms of neuronal death are not fully established.

Distinguish demonstrated propagation from incompletely understood neurotoxicity.

Slide 32 · From molecular lesion to brain dysfunction

Misfolded PrP spreads

PrP aggregates accumulate

Spongiform change + neuronal loss

Progressive neurologic deficits

The causal pathway is supported overall; Intermediate cellular steps remain incompletely explained.

Slide 33 · The major tissue compartments involved

Cerebral cortex

Deep gray matter

Cerebellum

Spongiform degeneration

Spongiform degeneration

PrP amyloid plaques

Cortical and deep gray-matter spongiform change occurs across prion diseases; Plaques are particularly useful when evaluating vCJD.

Slide 34 · Spongiform transformation is a central lesion

Microscopy reveals numerous apparently empty vacuoles scattered within gray matter.

Vacuoles vary in size and are distributed unevenly through the neuropil.

The appearance gives the tissue its characteristic sponge-like quality.

Spongiform degeneration is shared with other prion disorders; It is not vCJD-specific.

Slide 35 · Histologic principle: Spongiform change

Numerous neuropil vacuoles of variable size, without an obligatory central plaque

The open circles denote apparent empty spaces in neuropil, not extracellular PrP plaques.

Schematic — not a histologic specimen

Slide 36 · Neuropil vacuoles are not inflammatory exudates

CJD-related microscopic holes arise in the neuropil and sometimes neuronal cell bodies.

Electron microscopy localizes vacuoles to membrane-bound compartments in neuronal processes.

Microscopic vacuolation is accompanied by a notable absence of inflammation.

The apparent spaces should not be confused with nonspecific tissue processing defects.

Slide 37 · Neuronal loss accompanies advanced spongiform change

Progressive tissue injury causes loss of neurons in involved gray-matter regions.

Reactive gliosis follows destruction of neural tissue.

Advanced lesions can become confluent and cyst-like (status spongiosus).

Rapidly fatal cases may show major microscopic injury without conspicuous gross atrophy.

Slide 38 · Reactive gliosis contrasts with minimal inflammation

Reactive glial changes accompany neurodegeneration.

Typical prion pathology does not show prominent inflammatory infiltrates.

This helps separate protein-misfolding pathology from inflammatory encephalitis patterns.

Absence of inflammation does not identify the causative prion strain by itself.

Slide 39 · Kuru plaques reflect extracellular PrP aggregation

Aggregated abnormal PrP forms an extracellular plaque

Plaques represent abnormal prion-protein deposits rather than amyloid-β plaques.

Schematic — not a histologic specimen

Slide 40 · Why florid plaques matter in vCJD

Kuru-type PrP amyloid plaques are prominent in variant CJD.

The cerebral cortex may contain numerous plaques surrounded by vacuolation.

The combined plaque-and-vacuole pattern is termed a florid plaque.

Numerous florid plaques are a distinguishing neuropathologic feature of vCJD.

Slide 41 · Florid plaque: Interpret the surrounding vacuoles

Florid plaque = amyloid core with surrounding vacuolation

Read the lesion as a PrP-rich plaque with adjacent spongiform change, not as a tumor or abscess.

Schematic — not a histologic specimen

Slide 42 · Cortical plaque distribution is diagnostically useful

General prion diseases

Variant CJD

Spongiform vacuolation may involve cerebral and deep gray matter.

Kuru plaques often localize to the cerebellum.

Plaque abundance varies among disorders.

Cortical kuru-type plaques can be abundant.

Florid plaques accompany neuropil vacuolation.

Cerebral distribution helps distinguish the variant disease.

Slide 43 · Amyloid stains highlight deposits, not the whole mechanism

Extracellular PrP aggregates may stain with Congo red and PAS.

A positive amyloid reaction supports the nature of the deposited material.

Plaque recognition still requires anatomical and morphologic context.

Amyloid positivity alone cannot identify vCJD without other evidence.

Slide 44 · PrP immunohistochemistry clarifies protein identity

Prion-protein immunostaining establishes the nature of tissue deposits.

Controlled proteinase K treatment helps demonstrate resistant pathogenic PrP.

Immunostaining should be interpreted beside routine histology and lesion pattern.

The presence of abnormal PrP supports prion disease; Variant classification needs correlation.

Slide 45 · Integrating the histologic and biochemical findings

Finding

Meaning

Interpretive caution

Spongiform vacuoles

Shared pattern of prion degeneration

Not specific to vCJD

Florid plaques

Kuru-type amyloid with surrounding vacuoles

Characteristic variant pattern

PrP immunostaining

Identifies disease-related prion deposits

Needs tissue-context interpretation

Limited inflammation

Fits classic prion pathology

Not a standalone criterion

Slide 46 · Microscopic injury may exceed visible gross atrophy

Gross examination

Microscopy

Rapidly progressive disease may leave little obvious atrophy.

Atrophy can be more extensive after unusually prolonged illness.

Normal-looking gross tissue does not exclude prion pathology.

Neuropil vacuoles may be extensive.

Neuronal loss and reactive gliosis are demonstrable.

PrP-rich amyloid plaques enable more specific interpretation.

Slide 47 · What—and what it does not

Abundant cortical kuru plaques in vCJD.

It describes spongiform change, gliosis, neuronal loss, and abnormal PrP.

The supplied source does not provide validated numerical plaque thresholds.

It also does not supply embedded, reusable digital photomicrographs.

Slide 48 · A suspected case requires clinical–pathologic integration

Raises suspicion

Supports / establishes diagnosis

Young patient with progressive neuropsychiatric disorder.

Painful sensory complaints followed by neurologic signs.

Potential BSE-related exposure in the history.

Characteristic MRI or other corroborating studies.

Prion-associated pathologic and immunostaining abnormalities.

Definitive diagnosis requires brain-tissue pathology.

Slide 49 · MRI: The pulvinar sign

Bilateral posterior thalamic signal abnormality is a useful imaging clue.

The finding can support suspected vCJD in the appropriate clinical syndrome.

Imaging features do not replace neuropathologic confirmation.

MRI interpretation must account for alternative causes of thalamic abnormality.

Slide 50 · EEG does not behave identically in the two syndromes

Classic CJD

Variant CJD

Periodic sharp-wave complexes may be observed.

The EEG may contribute to evaluation of rapidly progressive dementia.

A nondiagnostic EEG cannot exclude a prion disorder.

Characteristic periodic complexes are often absent.

EEG is frequently nonspecific or diffusely abnormal.

The absence of classic CJD EEG changes fits the variant clinical pattern.

Slide 51 · Anatomic context matters for suspected cases

Neurologic findings indicate multi-region brain dysfunction.

The MRI pulvinar sign directs attention toward posterior thalamic abnormalities.

The pathologic pattern still requires consideration of cerebral and cerebellar lesions.

No single clinical, imaging, or histologic observation should be interpreted alone.

Slide 52 · Lymphoid tissue involvement changes surveillance logic

In vCJD, disease-associated prion protein can be detected outside brain tissue.

CDC contrasts relatively accessible lymphoid PrP in vCJD with classic CJD.

Peripheral involvement is compatible with preclinical infectivity.

This finding informs safety policy, but is not a substitute for full diagnostic evaluation.

Slide 53 · Neuropathology establishes definite vCJD

Widespread kuru-type amyloid plaques with surrounding vacuoles form florid plaques.

Spongiform degeneration occurs with extensive abnormal PrP deposition.

Characteristic features are assessed in cerebral and cerebellar tissue.

CDC states definite vCJD requires neuropathologic examination.

Slide 54 · Different investigations answer different questions

Evaluation

Primary contribution

Limitation

History/examination

Syndromic and exposure-based suspicion

Not confirmatory

Brain MRI

Supports pattern recognition

Not pathognomonic

EEG

Assesses physiologic abnormalities

Often nonspecific in vCJD

Neuropathology + PrP

Definitive tissue characterization

Requires brain tissue

Slide 55 · Clinical reasoning without overstating a test

Progressive clinical phenotype

Exposure + MRI/EEG context

Alternative etiologies assessed

Specialist prion evaluation

Definite vCJD rests on neuropathologic criteria, not on a single premortem test.

Slide 56 · Common overinterpretations to avoid

Young age is suggestive, not sufficient for diagnosis.

Psychiatric symptoms alone are common and nonspecific.

Spongiform change alone does not distinguish variant from all other prion diseases.

A compatible MRI finding supports a hypothesis; It is not a pathologic verdict.

Slide 57 · Primary and secondary prevention target different risks

Preventing animal-to-human exposure

Preventing human-to-human transmission

Control BSE in cattle and relevant animal-derived food chains.

Reduce opportunities for human exposure to infected material.

Public-health measures followed recognition of the UK outbreak.

Account for potential preclinical blood infectivity.

Apply relevant donor and product safety safeguards.

Recognize that lack of symptoms does not guarantee no infectivity.

Slide 58 · Why incidence declined after the outbreak

The UK incidence of vCJD peaked around 2000 in the Robbins account.

After controls were implemented, the observed incidence fell sharply.

The decline is consistent with successful reduction of relevant exposures.

Continued surveillance remains important because incubation can be prolonged.

Slide 59 · Integrated case: Prioritize the decisive evidence

Illustrative teaching vignette (not a real patient)

A young adult has progressive behavioral disturbance, later ataxia, and a supportive bilateral posterior thalamic MRI abnormality. Histology shows florid cortical PrP plaques with spongiform degeneration.

Clinical interpretation

Which findings establish high pretest clinical suspicion?

Which findings provide definitive tissue-level classification?

Slide 60 · Case interpretation: Weigh evidence in sequence

The clinical phenotype and age justify considering vCJD.

MRI can strengthen suspicion but should not be treated as proof.

Florid plaques, spongiform change, and abnormal PrP create the defining tissue pattern.

A possible BSE exposure supplies epidemiologic context rather than a replacement for pathology.

Slide 61 · Distinguishing vCJD from alternative processes

Other prion disease forms

Nonprion neurologic disease

Share abnormal PrP and spongiform degeneration.

May have different age profile, clinical sequence, and plaque burden.

Use disease context rather than one common lesion.

Some can present with psychiatric or cognitive symptoms.

MRI and clinical progression may overlap nonspecifically.

Abnormal resistant PrP in the correct morphology changes the diagnosis.

Slide 62 · High-yield clinicopathologic synthesis

BSE-associated transmission distinguishes vCJD etiologically.

Early psychiatric/behavioral disease in younger individuals differs from classic CJD.

PrPˢᶜ templating and accumulation drive a shared prion mechanism.

Numerous cortical florid plaques with spongiform change characterize the variant.

Diagnosis requires integration; Brain pathology provides definitive confirmation.

Slide 63 · Five interpretation rules for practice

Trace the exposure history without assuming causation from geography alone.

Attend to symptom sequence rather than one presenting complaint.

Separate useful MRI signs from histologic confirmation.

Distinguish universal spongiform pathology from the vCJD-enriched plaque pattern.

Document whether each assertion derives from textbook, current guidance, or inference.

Slide 64 · Primary references and image access

Robbins, Cotran & Kumar

Pathologic Basis of Disease, 11th edition (2026), Chapter 28, pp. 1159–1161.

Prion diseases; classic CJD; variant CJD; morphology and Figures 28.34–28.35.

CDC — Clinical Overview of Variant CJD

Centers for Disease Control and Prevention; updated November 12, 2024.

Clinical comparison, imaging interpretation, diagnostic criteria, and public health.

Genuine H&E examples: CDC Public Health Image Library IDs 10130 and 10131 (public domain); sources listed in presenter notes. No diagnostic micrograph is reproduced in this deck.